Otros idiomas Orexo AB

Acciones

ORX

SE0000736415

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:49 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
16,54 ^SEK	-2,71 %		+0,12 %	+6,99 %

17/04	Orexo amplía la protección de la patente de su producto de epinefrina nasal en polvo OX640 en EE.UU.	CI
02/04	La sueca Orexo se dispone a amortizar anticipadamente sus bonos con vencimiento en 2025	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Report from Orexo AB's annual general meeting, 26 April 2024	26/04
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	17/04
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	17/04
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	17/04
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	02/04
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	02/04
Orexo publishes the Annual and Sustainability Report for 2023	28/03
Orexo AB Announces Board Resignations	22/03
Correction: Notice of Annual General Meeting of Orexo	15/03
Notice of Annual General Meeting of Orexo	15/03
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	14/03
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	13/03
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	13/03
Orexo Plans SEK500 Million New Social Bond Issuance, Tender Offer	08/03
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	08/03
Orexo strengthens its sustainability work by establishing a social financing framework	08/03
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	12/02
Orexo and Sobi agree to advance feasibility study with AmorphOX	12/02
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	12/02
Orexo Interim Report Q4 2023, incl. Full Year Report	08/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Orexo AB

Acciones

ORX

SE0000736415

Otros idiomas

Filtros